Kura Oncology, Inc. (NASDAQ:KURA) traded up 8.9% during mid-day trading on Monday . The stock traded as high as $16.75 and last traded at $16.45. 507,800 shares were traded during trading, an increase of 74% from the average session volume of 291,394 shares. The stock had previously closed at $15.10.

Several equities research analysts recently issued reports on the company. Cann reiterated a “buy” rating on shares of Kura Oncology in a report on Wednesday, November 8th. Leerink Swann reiterated an “outperform” rating and set a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating and set a $7.25 price target for the company. in a report on Wednesday, August 23rd. Citigroup Inc. set a $13.00 price target on Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $17.20.

The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). equities analysts expect that Kura Oncology, Inc. will post -1.45 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. lifted its position in shares of Kura Oncology by 61.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock valued at $587,000 after buying an additional 14,900 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $802,000. EAM Investors LLC bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $2,884,000. Artal Group S.A. bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $1,495,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Kura Oncology by 89.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 59,281 shares of the company’s stock valued at $886,000 after purchasing an additional 28,031 shares during the period. 39.11% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Kura Oncology, Inc. (KURA) Trading 8.9% Higher” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/kura-oncology-inc-kura-trading-8-9-higher/1700893.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.